Literature DB >> 31473917

The Genomic Landscape of Sporadic Prolactinomas.

Sunita M C De Sousa1,2,3, Paul P S Wang4, Stephen Santoreneos5, Angeline Shen6,7, Christopher J Yates6,7, Milena Babic8, Leila Eshraghi8,4,9, Jinghua Feng4,9, Barbara Koszyca10, Samuel Roberts-Thomson11, Andreas W Schreiber4,9,12, David J Torpy13,14, Hamish S Scott8,14,4,9.   

Abstract

Somatic GNAS and USP8 mutations have been implicated in sporadic somatotrophinomas and corticotrophinomas, respectively. However, no genes are known to be recurrently mutated in sporadic prolactinomas. The prevalence of copy number variants (CNV), which is emerging as a mechanism of tumorigenesis in sporadic pituitary adenomas in general, is also unclear in prolactinomas. To characterize the genetic events underpinning sporadic prolactinomas, we performed whole exome sequencing of paired tumor and germline DNA from 12 prolactinoma patients. We observed recurrent large-scale CNV, most commonly in the form of copy number gains. We also identified sequence variants of interest in 15 genes. This included the DRD2, PRL, TMEM67, and MLH3 genes with plausible links to prolactinoma formation. Of the 15 genes of interest, CNV was seen at the gene locus in the corresponding tumor in 10 cases, and pituitary expression of eight genes was in the top 10% of tissues. However, none of our shortlisted somatic variants appeared to be classical driver mutations as no variant was found in more than one tumor. Future directions of research include mechanistic studies to investigate how CNV may contribute to prolactinoma formation, larger studies of relevant prolactinoma subsets according to clinical characteristics, and additional genetic investigations for aberrations not captured by whole exome sequencing.

Entities:  

Keywords:  Copy number variation; Driver mutation; Loss of heterozygosity; Pituitary adenoma; Prolactinoma; Whole exome sequencing

Mesh:

Year:  2019        PMID: 31473917     DOI: 10.1007/s12022-019-09587-0

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  34 in total

1.  A role for MLH3 in hereditary nonpolyposis colorectal cancer.

Authors:  Y Wu; M J Berends; R H Sijmons; R G Mensink; E Verlind; K A Kooi; T van der Sluis; C Kempinga; A G van dDer Zee; H Hollema; C H Buys; J H Kleibeuker; R M Hofstra
Journal:  Nat Genet       Date:  2001-10       Impact factor: 38.330

2.  Role of a p53 polymorphism in the development of nonfunctional pituitary adenomas.

Authors:  Garima Yagnik; Arman Jahangiri; Rebecca Chen; Jeffrey R Wagner; Manish K Aghi
Journal:  Mol Cell Endocrinol       Date:  2017-02-16       Impact factor: 4.102

3.  Mutations in the deubiquitinase gene USP8 cause Cushing's disease.

Authors:  Martin Reincke; Silviu Sbiera; Akira Hayakawa; Marily Theodoropoulou; Andrea Osswald; Felix Beuschlein; Thomas Meitinger; Emi Mizuno-Yamasaki; Kohei Kawaguchi; Yasushi Saeki; Keiji Tanaka; Thomas Wieland; Elisabeth Graf; Wolfgang Saeger; Cristina L Ronchi; Bruno Allolio; Michael Buchfelder; Tim M Strom; Martin Fassnacht; Masayuki Komada
Journal:  Nat Genet       Date:  2014-12-08       Impact factor: 38.330

4.  Biallelic variants in the ciliary gene TMEM67 cause RHYNS syndrome.

Authors:  Francesco Brancati; Letizia Camerota; Emma Colao; Virginia Vega-Warner; Xiangzhong Zhao; Ruixiao Zhang; Irene Bottillo; Marco Castori; Alfredo Caglioti; Federica Sangiuolo; Giuseppe Novelli; Nicola Perrotti; Edgar A Otto
Journal:  Eur J Hum Genet       Date:  2018-06-11       Impact factor: 4.246

5.  Germline USP8 Mutation Associated With Pediatric Cushing Disease and Other Clinical Features: A New Syndrome.

Authors:  Michal Cohen; Rebecca Persky; Rachel Stegemann; Laura C Hernández-Ramírez; Deena Zeltser; Maya B Lodish; Anlu Chen; Margaret F Keil; Christina Tatsi; Fabio R Faucz; David A Buchner; Constantine A Stratakis; Dov Tiosano
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

6.  Corticotroph Pituitary Carcinoma in a Patient With Lynch Syndrome (LS) and Pituitary Tumors in a Nationwide LS Cohort.

Authors:  Daniel Bengtsson; Patrick Joost; Christos Aravidis; Marie Askmalm Stenmark; Ann-Sofie Backman; Beatrice Melin; Jenny von Salomé; Theofanis Zagoras; Samuel Gebre-Medhin; Pia Burman
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

7.  No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia.

Authors:  A Raitila; M Georgitsi; A Karhu; K Tuppurainen; M J Mäkinen; K Birkenkamp-Demtröder; K Salmenkivi; T F Orntoft; J Arola; V Launonen; P Vahteristo; L A Aaltonen
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

8.  Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses.

Authors:  Chheng-Orn Evans; Carlos S Moreno; Xianquan Zhan; Michael T McCabe; Paula M Vertino; Dominic M Desiderio; Nelson M Oyesiku
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

9.  Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability.

Authors:  Anne Wierinckx; Etienne Delgrange; Philippe Bertolino; Patrick François; Philippe Chanson; Emmanuel Jouanneau; Joël Lachuer; Jacqueline Trouillas; Gérald Raverot
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-30       Impact factor: 5.555

10.  Whole-exome sequencing studies of nonfunctioning pituitary adenomas.

Authors:  Paul J Newey; M Andrew Nesbit; Andrew J Rimmer; Rosie A Head; Caroline M Gorvin; Moustafa Attar; Lorna Gregory; John A H Wass; David Buck; Niki Karavitaki; Ashley B Grossman; Gilean McVean; Olaf Ansorge; Rajesh V Thakker
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

View more
  5 in total

Review 1.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

Review 2.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

3.  Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.

Authors:  Hélène Lasolle; Mad-Hélénie Elsensohn; Anne Wierinckx; Eudeline Alix; Clément Bonnefille; Alexandre Vasiljevic; Christine Cortet; Bénédicte Decoudier; Nathalie Sturm; Stephan Gaillard; Amandine Ferrière; Pascal Roy; Emmanuel Jouanneau; Philippe Bertolino; Claire Bardel; Damien Sanlaville; Gérald Raverot
Journal:  Acta Neuropathol Commun       Date:  2020-11-10       Impact factor: 7.801

Review 4.  Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.

Authors:  Betina Biagetti; Rafael Simò
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

5.  Whole exome sequencing reveals novel risk genes of pituitary neuroendocrine tumors.

Authors:  Raitis Peculis; Vita Rovite; Kaspars Megnis; Inga Balcere; Austra Breiksa; Jurijs Nazarovs; Janis Stukens; Ilze Konrade; Jelizaveta Sokolovska; Valdis Pirags; Janis Klovins
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.